With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...

With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on ...

The Trump administration's health policy changes emphasized market-driven approaches, including Medicaid work requirements ...

Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...

Multidisciplinary care helps manage cardiac risks in breast cancer, allowing patients to continue treatment safely, says Eric H. Yang, MD.

Significant racial and ethnic disparities were observed in both the incidence and psychological effects of persistent chemotherapy-induced alopecia (PCIA) among women with breast cancer, with Asian ...

The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...

The primary outcome was a collection of adverse outcomes that included intensive care unit (ICU) admission, uterine rupture, maternal blood transfusion, and unplanned hysterectomies. The rate of ...

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care ...

With the debut of TrumpRx.gov and other moves, the administration is steering the nation toward a market-driven, “America ...